Invest in intelligence that delivers

Patients with Moderate-to-Severe SLE are Increasingly Being Treated with Biologic Therapies Such as GSK’s Benlysta and AstraZeneca’s Saphnelo, According to Spherix Global Insights

In the third annual patient chart analysis, major treatment shifts in biologic use and average daily steroid dose were observed. EXTON, Pa., June 15, 2023 — Systemic lupus erythematosus (SLE) patients present significant challenges in management, given the complexity of the condition and few effective treatment options available. However, recently approved lupus therapies and a […]

Sanofi/Regeneron’s Dupixent Performance in Eosinophilic Esophagitis is Paving the Way for Future Therapies in an Underserved and Growing Market, According to Spherix Global Insights

Spherix’s tracking data reveals use of Dupixent in EoE has tripled since its approval.  Exton, PA., April 3, 2023 – In 2017, Sanofi/Regeneron announced the FDA approval for the first biologic agent to treat atopic dermatitis (AD). The success of that drug, Dupixent (dupilumab), inspired competitors to scramble for a place in the AD market, […]

Genentech’s Vabysmo Well-Received Amongst Ophthalmologists, but Use Continues to Lag the Competition, According to Spherix Global Insights

Despite a very satisfied Vabysmo user-base, Regeneron’s 8mg aflibercept is already highly anticipated by ophthalmologists and likely to throw a wrench into Vabysmo’s positive trajectory. EXTON, Pa., March 29, 2023 – According to Spherix Global Insights’ Launch Dynamix™: Vabysmo service, to no surprise, Regeneron’s Eylea continues to lead the charge in both the nAMD and […]

Familiarity with GSK’s Jesduvroq® (daprodustat) Likely to Be Strong Driver of Adoption in Dialysis, According to Spherix Global Insights

According to Spherix Global Insights, the latest findings from RealTime Dynamix™: Renal Anemia report indicate that the more familiar nephrologists are with Jesduvroq, the more bullish they are about uptake. Exton, PA., March 27, 2023 – In the 32nd wave of ongoing tracking of the U.S. Renal Anemia market, Spherix surveyed 207 US nephrologists about […]

Eli Lilly Poised to Nab First to Market Advantage with it’s IL-23 Inhibitor Mirikizumab in Ulcerative Colitis, Creating an Opportunity to Build a Loyal Base Ahead of AbbVie and Janssen’s Respective IL-23 Entries, According to Spherix Global Insights

Gastroenterologists project mirikizumab will play a significant role in the treatment of ulcerative colitis Exton, PA., March 15, 2023 – In 2021, Eli Lilly (“Lilly”) announced it would forego pursuing a psoriasis indication for it’s IL-23 inhibitor mirikizumab, strategically focusing instead on the inflammatory bowel disease (IBD) market. The decision created an opportunity to deliver […]

Ophthalmology Times: Impact of biosimilar availability on the US ophthalmology markets

Continued education and financial incentives will become essential if biosimilars are to become a mainstay in ophthalmological markets, according to a recent report. A new Spherix Global Insights study reported the results of a survey of 80 ophthalmologists in the US that sought feedback on the use and perceptions of biosimilar agents and their impact […]

Can BMS’ Zeposia Cement a Defensible Market Position in Ulcerative Colitis Ahead of Pfizer’s Potential Rival S1P treatment, etrasimod?

Zeposia is only capitalizing on a small portion of opportunity in the US ulcerative colitis market according to Spherix Global Insights EXTON, Pa., February 9, 2023 – Analysis from Spherix Global Insights quarterly market tracker, RealTime Dynamix™: Ulcerative Colitis, reveals that at twenty (20) months after the FDA approved Zeposia for use in Ulcerative Colitis […]

U.S. Nephrologists Report Mixed Reactions to the Approval of GSK’s Jesduvroq® (daprodustat) for the Treatment of Anemia in Dialysis Patients, According to Spherix Global Insights

110 U.S. nephrologists provided immediate feedback regarding GSK’s newly approved HIF-PH inhibitor – the first approved in the United States – for the treatment of anemia in dialysis patients.  EXTON, Pa., February 9, 2023 – Since 2017, Spherix Global Insights has been monitoring the U.S. renal anemia market landscape, capturing nephrologists’ perceptions and opinions of […]

Major Shifts in Management of Patients with Lupus Nephritis Spurred by Availability of Aurinia Pharmaceutical’s Lupkynis and GSK’s Benlysta, According to Spherix Global Insights

Latest patient-level data analysis by Spherix Global Insights showcases year over year shifts in nephrology and rheumatology practice patterns alongside strong appetite for new LN pipeline drugs.  EXTON, Pa., January 20, 2023 /PRNewswire/ — With the approvals of GlaxoSmithKline’s Benlysta (belimumab) in lupus nephritis (LN) at the end of 2020 and Aurinia’s Lupkynis (voclosporin) at […]

Sign up for alerts, market insights and exclusive content in your inbox.

Spherix is excited to announce our expansion into an additional, rapidly evolving specialty market:


Throughout 2024, we will be publishing over
10 groundbreaking studies covering a wide range of indications within classical hematology.